Laurence Tokaz, MD
Medical Oncology · Austin, TXNPI 1124060256
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Takeda Pharmaceuticals U.S.A., Inc. accounts for 63.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $14,857 and has fallen 99.9% since, to $19 in 2025.
Across 37 payments — averaging $411.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Gilead$5K
- Genentech USA, Inc.$123
- Johnson & Johnson$112
- E.r. Squibb & Sons, L.L.C.$56
- Bristol Myers Squibb$55
- plus $139 from 7 others
What the payments were for
- Consulting fees$3,30022%
- Speaking & faculty fees$8,25054%
- Travel & lodging$2,82519%
- Food & beverage$6875%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $9,708 |
| Gilead(2 entities) | 12 | $5,026 |
| Genentech USA, Inc. | 1 | $123 |
| Johnson & Johnson | 2 | $112 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Bristol Myers Squibb | 3 | $55 |
| AstraZeneca | 2 | $39 |
| Novartis | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| EMD Serono, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,219 in reported general payments places this provider in the 65th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Austin
- Sue EckhardtAustin$1.5M
- Miguel AlbinoAustin$322K
- Jason MelearAustin$229K
- Andrew BrennerAustin$125K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.